Does AI Data Deal And New CMO Hire Change The Bull Case For Recursion (RXRX)?
Recursion Pharmaceuticals (RXRX) recently expanded its partnership with Citeline for AI-powered drug development and appointed Vicki Goodman, M.D., as its new Chief Medical Officer, effective April 6, 2026. These moves aim to strengthen clinical execution, especially in oncology. While these developments are seen as positive for near-term clinical studies, the company still faces significant cash burn, a limited cash runway into late 2027, and reliance on external funding.
A Look At Recursion Pharmaceuticals (RXRX) Valuation As Investor Narratives Diverge
Recursion Pharmaceuticals (RXRX) is experiencing divergent investor narratives regarding its valuation, with some investors finding it overvalued at $3.07 based on a fair value of $1.97, while Simply Wall St's DCF model suggests it is undervalued with a fair value of $9.54. The article highlights the company's clinical stage pipeline and revenue, prompting investors to scrutinize the numbers and warnings before making investment decisions.
Vanguard disaggregates holdings; (RXRX) Schedule 13G/A shows 0 shares
The Vanguard Group filed an amended Schedule 13G/A for Recursion Pharmaceuticals Inc (RXRX), reporting 0 beneficial shares and 0% ownership. This change is due to an internal realignment within Vanguard, leading to disaggregated reporting by its subsidiaries, as per SEC Release No. 34-39538. The filing clarifies that this does not indicate a sale of shares but rather a restructuring of how Vanguard's holdings are reported by its various entities.
New Recursion CMO Puts Oncology Experience At Center Of Investor Focus
Recursion Pharmaceuticals has appointed Vicki Goodman, M.D., as its new Chief Medical Officer, bringing over 20 years of oncology drug development experience. This appointment is significant given Recursion's recent weak share performance and its clinical pipeline nearing key decision points. Investors will be watching closely to see how Dr. Goodman's expertise translates into improved trial design, regulatory interactions, and resource allocation, potentially influencing the company's path forward despite facing execution risks.
[Form 4] RECURSION PHARMACEUTICALS, INC. Insider Trading Activity
RECURSION PHARMACEUTICALS, INC. director Christopher Gibson converted 40,000 shares of Class B Common Stock into Class A Common Stock and subsequently sold these 40,000 Class A shares at $3.25 each through an open-market transaction under a Rule 10b5-1 trading plan. After these transactions, Gibson directly holds 906,556 shares of Class A Common Stock and 4,483,334 shares of Class B Common Stock. The filing also details various derivative securities and stock options held by Gibson, along with their vesting schedules and beneficial ownership entities.
Assessing Recursion Pharmaceuticals (RXRX) Valuation After Prolonged Share Price Weakness
Recursion Pharmaceuticals (RXRX) has experienced a significant share price pullback, leading to varied opinions on its valuation. While a prevailing narrative labels the stock as 65% overvalued with a fair value of US$1.97 due to insider selling and unmet expectations, Simply Wall St's DCF model suggests a fair value of US$9.45. This discrepancy highlights the split sentiment among investors regarding the company's future prospects and whether the current weakness represents a buying opportunity.
Director reports multiple Class A share sales — RXRX (NASDAQ: RXRX)
A Form 144 filing by Recursion Pharmaceuticals (RXRX) indicates that a director sold 160,000 Class A founder shares across four separate transactions in January and February 2026. These sales, each for 40,000 shares, generated gross proceeds totaling $652,000. Christopher C. Gibson is identified as the reporting person associated with these transactions.
CFO of Recursion Pharmaceuticals (RXRX) sells 7,956 shares under 10b5-1 plan
Recursion Pharmaceuticals' CFO, Ben R. Taylor, reported selling 7,956 shares of Class A Common Stock at $3.39 per share on March 17, 2026, as part of a pre-arranged Rule 10b5-1 trading plan. Additionally, on March 16, 2026, 7,075 shares were disposed of to cover tax obligations related to restricted stock units. Following these transactions, Taylor directly holds 1,180,318 shares of the company.
A Look At Recursion Pharmaceuticals (RXRX) Valuation After Q4 Beat And AI Clinical Progress
Recursion Pharmaceuticals (RXRX) reported Q4 revenue above consensus and highlighted progress in its AI-native drug discovery platform, with a cash runway extending into early 2028. Despite this, the company's share price performance has been weak, leading to mixed sentiment regarding its valuation. While a popular narrative suggests RXRX is overvalued at $3.45 with a fair value of $1.97, Simply Wall St's DCF model indicates a fair value of $9.50, suggesting the stock is trading at a significant discount.
Recursion (NASDAQ: RXRX) director sells 170,000 shares in open market
Recursion Pharmaceuticals director Blake Borgeson sold 170,000 shares of Class A common stock at an average price of $3.46 per share on March 3, 2026. Following this transaction, Borgeson directly owns 6,259,863 shares of the company. The sale was executed as an open-market transaction and was disclosed in an SEC Form 4 filing.
Assessing Recursion Pharmaceuticals (RXRX) Valuation After Earnings Jump And New Equity Offering Plans
Recursion Pharmaceuticals (RXRX) recently reported significant increases in Q4 2025 sales and revenue, along with a narrower net loss, though full-year net losses widened. The company also announced plans for a $300 million at-the-market equity offering and a $68.57 million ESOP-related shelf registration, which could influence funding and potential dilution. While some market narratives suggest the stock is overvalued at $1.97 compared to its current share price of $3.64, a discounted cash flow model by Simply Wall St indicates it might be undervalued at $9.47.
Recursion Pharmaceuticals (RXRX) Is Down 6.1% After Insider Sale And New ATM Equity Program - Has The Bull Case Changed?
Recursion Pharmaceuticals (RXRX) recently reported a significant net loss and announced a new US$300 million at-the-market equity offering, coupled with an insider share sale, causing a 6.1% stock drop. The article evaluates if these financial developments and dilution concerns alter the investment narrative, which hinges on the success of its AI-driven drug discovery platform and clinical progress for REC‑4881. Forecasts suggest a potential 98% upside based on fair value, but significant funding needs and dependence on external capital remain key risks.
RECURSION PHARMACEUTICALS Director Sells 170,000 Shares
A director at RECURSION PHARMACEUTICALS, Blake Borgeson, sold 170,000 shares of Class A Common Stock for $588,200 on March 3, 2026. This transaction leaves Borgeson with 6,259,863 shares directly owned in the company. The sale was reported in an SEC Form 4 filing.
Blake Borgeson disposes 440K Class A shares (RXRX) in two blocks
Blake Borgeson, an insider at Recursion Pharmaceuticals (RXRX), sold a total of 440,000 Class A shares in two separate blocks. The transactions, reported via a Form 144 filing, occurred on January 6, 2026, and February 3, 2026, with gross proceeds of $959,200 and $924,000 respectively. The filing also notes earlier issuer-designated Class A founder/compensation share entries for Borgeson.
Assessing Recursion Pharmaceuticals (RXRX) After A 51% One Year Share Price Decline
This article analyzes Recursion Pharmaceuticals (RXRX) following a 51% share price decline over the past year. It examines the company's valuation using a Discounted Cash Flow (DCF) model and Price/Sales ratio, finding it undervalued by DCF but overvalued by P/S compared to industry averages. The piece also discusses two contrasting "Narratives" for RXRX – one optimistic with a fair value of $7.00 per share, and another skeptical pegging it at $1.97 per share, highlighting the wide range of investor sentiment and assumptions for the AI-driven drug discovery company.
How Investors May Respond To Recursion Pharmaceuticals (RXRX) Extending Cash Runway With New Equity Programs
Recursion Pharmaceuticals (RXRX) recently reported 2025 full-year results, showing a net loss of US$644.76 million and announcing a US$300 million at-the-market offering along with a US$68.57 million shelf registration. This move, combined with cost controls and partnerships, extends its cash runway into early 2028. While this de-risks funding in the short term, the company's high cash burn and reliance on external capital mean investors remain focused on clinical progress and potential dilution.
Recursion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Recursion (Nasdaq: RXRX) announced its fourth-quarter and full-year 2025 financial results, highlighting the clinical validation of its AI Operating System in FAP and the achievement of its fifth program milestone with Sanofi. The company reported $754 million in cash and cash equivalents, extending its financial runway into early 2028 without additional financing, attributing this to disciplined capital allocation alongside platform and program investments. Recursion is advancing a diversified pipeline with wholly-owned and partnered programs, driven by its end-to-end AI-native Recursion OS across various therapeutic areas.
Recursion Pharmaceuticals Q4 Earnings Report: What Investors Need to Know
Recursion Pharmaceuticals (NASDAQ: RXRX) announced its Q4 earnings on February 25, 2026, beating estimated earnings by 30.0% with an EPS of $-0.21. The company's revenue was up by $30.99 million compared to the same period last year. This report provides an overview of the company's recent financial performance for investors.
Recursion Pharmaceuticals Q3 Loss Deepens Narrative Of Heavy Spending Over Limited US$5.2m Revenue
Recursion Pharmaceuticals (RXRX) reported a Q3 FY 2025 net loss of US$162.3 million on revenue of US$5.2 million, highlighting its continued investment mode rather than profitability. The company's trailing 12-month revenue of US$43.7 million is dwarfed by a US$715.5 million net loss, raising concerns about ongoing cash outflows and the lack of forecasted profitability by analysts over the next three years. Despite a high forecast revenue growth of 52.8% per year driven by its AI drug discovery platform, the company's escalating losses challenge the bullish narrative, while its valuation shows a tension between a market price significantly below its DCF fair value and a high P/S ratio compared to peers.
Recursion Pharmaceuticals's Earnings Outlook
Recursion Pharmaceuticals (NASDAQ: RXRX) is scheduled to release its quarterly earnings report on February 25, 2026. Analysts predict an EPS of $-0.30. Investors will be focused on whether the company surpasses estimates and provides positive guidance, as stock prices are heavily influenced by future projections.
Ben Taylor files to sell Class A shares (NASDAQ: RXRX) in Form 144
Ben Taylor, an insider at Recursion Pharmaceuticals (NASDAQ: RXRX), has filed a Form 144 indicating an intent to sell Class A common stock tied to restricted stock vesting expected on February 15, 2026. The filing also discloses a prior sale by Taylor of 21,383 shares on December 29, 2025, for $89,380.94. Fidelity Brokerage Services LLC is listed as the broker for these transactions.
Is The Exit Of Nvidia And Novo Holdings Altering The Investment Case For Recursion Pharmaceuticals (RXRX)?
The article discusses the recent exits of major investors Nvidia and Novo Holdings from Recursion Pharmaceuticals (RXRX) ahead of its Q4 2025 earnings and FDA discussions for REC-4881. It explores how these departures impact Recursion's investment narrative, perceived risk profile, and future fundraising, especially given the company's cash burn and reliance on external capital. Despite these concerns, the upcoming FDA meeting for REC-4881 remains a key catalyst, with analysts suggesting a significant upside to the current stock price.
Recursion Uses Inducement RSUs As Hiring And Valuation Signal For Investors
Recursion Pharmaceuticals is using inducement Restricted Stock Unit (RSU) awards to attract and retain talent in biotech and software, signaling ongoing hiring and investment in its workforce. This strategy aims to align new employees with shareholder outcomes but also raises concerns about potential share dilution. Investors are advised to monitor future disclosures regarding total share count and equity compensation expenses.
RECURSION PHARMACEUTICALS Director Sells 220,000 Shares
Blake Borgeson, a Director at RECURSION PHARMACEUTICALS (RXRX), sold 220,000 shares of Class A Common Stock on February 3, 2026, for a total of $924,000. This transaction was carried out under a Rule 10b5-1 trading plan adopted in August 2025. Following the sale, Borgeson's direct ownership in the company stands at 6,429,863 shares.
A Look At Recursion Pharmaceuticals (RXRX) Valuation After New AI Bioengineering Market Study
Recursion Pharmaceuticals (RXRX) is highlighted in a new AI-driven bioengineering market study for its AI biology platform, despite recent weak share price performance. The stock is currently trading at $3.98, significantly below the analyst target of $7.00, suggesting it may be undervalued. However, its high P/S ratio compared to the industry indicates investors are already paying a premium.
Borgeson Blake sells Recursion Pharmaceuticals (RXRX) shares for $924k
Borgeson Blake, a director at Recursion Pharmaceuticals (NASDAQ:RXRX), sold 220,000 shares for $924,000 on February 3, 2026, as per a Rule 10b5-1 trading plan. This sale occurred while RXRX shares had seen a 5% drop over the prior week and a 45% year-over-year decline. The company, despite holding more cash than debt, is not profitable and has a significant negative EBITDA.
Borgeson Blake sells Recursion Pharmaceuticals (RXRX) shares for $924k By Investing.com
Director Blake Borgeson sold 220,000 shares of Recursion Pharmaceuticals (RXRX) for $924,000 on February 3, 2026, though the current stock price is below his selling price and the company faces profitability challenges despite holding more cash than debt. This sale occurred while the company reported promising Phase 1b/2 TUPELO trial results for REC-4881, leading JPMorgan to upgrade the stock to Overweight with an $11.00 price target. Recursion Pharmaceuticals plans to present updated clinical data from the TUPELO trial in a December 8, 2025 webinar to provide further insights into the drug's safety and efficacy for familial adenomatous polyposis (FAP).
Borgeson Blake sells Recursion Pharmaceuticals (RXRX) shares for $924k
Director Blake Borgeson sold 220,000 shares of Recursion Pharmaceuticals (RXRX) for $924,000 on February 3, 2026, pursuant to a Rule 10b5-1 trading plan. This sale occurred as RXRX shares have declined, trading below Borgeson's selling price, despite recent promising TUPELO trial results for REC-4881 which led to a JPMorgan upgrade. The company, while cash-rich, is not profitable and has a negative EBITDA.
Recursion Pharmaceuticals Director Sells 220,000 Shares
Recursion Pharmaceuticals Director Blake Borgeson sold 220,000 shares of Class A Common Stock on January 6, 2026, for a total of $959,200. The transaction was conducted under a Rule 10b5-1 trading plan. Following the sale, Borgeson directly holds 6,649,863 shares in the company.
Recursion Pharma director Gibson sells $178,800 in stock By Investing.com
Christopher Gibson, a director at Recursion Pharmaceuticals Inc (NASDAQ:RXRX), sold 40,000 shares of Class A Common Stock for $178,800 and converted 40,000 Class B shares to Class A on January 20, 2026. Following these transactions, Gibson's direct and indirect holdings of Recursion Pharmaceuticals shares total over 1.7 million. This news comes as the company reported positive interim results for its investigational drug REC-4881 in treating familial adenomatous polyposis (FAP), leading to an "Overweight" upgrade from JPMorgan.
Recursion Pharma director Gibson sells $178,800 in stock By Investing.com
Director Christopher Gibson of Recursion Pharmaceuticals Inc (NASDAQ:RXRX) sold 40,000 shares of Class A Common Stock for $178,800 on January 20, 2026, and converted an equal number of Class B shares to Class A. JPMorgan upgraded Recursion Pharmaceuticals to Overweight with an $11 price target due to positive results from its TUPELO trial for REC-4881, showing significant polyp reduction in FAP patients, with further clinical data to be presented. This article was generated with the support of AI and reviewed by an editor.
Recursion Pharmaceuticals (RXRX) Valuation Check After Analyst Optimism Insider Buying And Nvidia AI Partnership
Recursion Pharmaceuticals (RXRX) is gaining attention due to positive analyst commentary, insider buying, and a strategic AI partnership with Nvidia, despite a mixed share price performance over the past year. The company is at a critical juncture, transitioning from a "science project" to a commercial-stage TechBio leader with validated clinical data and significant milestone payments. While analysts suggest it could be undervalued by approximately 62.1% with a fair value of $12.49 per share, this optimistic outlook hinges on unproven long-term profitability and successful late-stage trial outcomes.
Is Recursion (RXRX) Turning Nvidia-Backed AI Hype Into a Durable Drug Discovery Advantage?
The article discusses Recursion Pharmaceuticals, focusing on its AI-driven drug discovery platform, BioHive-2 supercomputer, and collaboration with Nvidia. It highlights analyst optimism and insider share purchases, acknowledging that current enthusiasm around Nvidia's backing appears sentiment-driven rather than fundamental. The piece also delves into the investment narrative, risks from persistent losses and dilution, and the varied fair value views on the stock.
Recursion Pharma director Gibson sells $178,800 in stock
Recursion Pharmaceuticals director Christopher Gibson sold 40,000 shares of Class A Common Stock for $178,800 on January 20, 2026, and converted 40,000 Class B shares to Class A. The company also reported positive Phase 1b/2 trial results for REC-4881 in treating familial adenomatous polyposis, leading JPMorgan to upgrade its stock to Overweight with an $11 price target. Recursion Pharmaceuticals plans to present further clinical data from the TUPELO trial on December 8, 2025.
Recursion Pharma director Gibson sells $178,800 in stock By Investing.com
Director Christopher Gibson of Recursion Pharmaceuticals Inc. sold 40,000 shares of Class A Common Stock for $178,800 on January 20, 2026, and also converted 40,000 shares of Class B to Class A Common Stock. Following these transactions, Gibson maintains significant direct and indirect holdings in the company. This news follows positive results from Recursion's TUPELO trial for REC-4881, leading to an "Overweight" upgrade from JPMorgan.
Recursion Pharma director Gibson sells $178,800 in stock
Director Christopher Gibson of Recursion Pharmaceuticals Inc. sold 40,000 shares of Class A Common Stock for $178,800 on January 20, 2026, and converted an equal number of Class B shares to Class A. Following these transactions, Gibson maintains substantial direct and indirect holdings in the company. Separately, Recursion Pharmaceuticals recently reported positive Phase 1b/2 TUPELO trial results for its drug REC-4881, leading to a JPMorgan upgrade, and plans to present updated clinical data in December 2025.
How Do Investors Really Feel About Recursion Pharmaceuticals Inc?
Recursion Pharmaceuticals Inc (RXRX) has seen a 7.8% increase in its short interest as a percent of float, now standing at 33.73% with 165.73 million shares sold short. This indicates a growing bearish sentiment among investors compared to its last report. The company's short interest is significantly higher than its peer group average of 12.95%, suggesting that despite a potential stock decline, traders should be aware of increased shorting activity.
Is It Time To Reassess Recursion Pharmaceuticals (RXRX) After Recent Share Price Weakness
This article analyzes Recursion Pharmaceuticals (RXRX) following recent share price weakness, suggesting it might be undervalued. Using a Discounted Cash Flow (DCF) analysis, the stock is estimated to be 49.8% undervalued, with an intrinsic value of $9.31 per share compared to its $4.67 market price. The Price to Book (P/B) ratio of 2.32x is below the industry average, and the article also introduces the concept of "Narratives" for investors to develop their own valuation based on financial forecasts.
Assessing Recursion Pharmaceuticals (RXRX) Valuation After JP Morgan Update And REC-4881 Clinical Milestones
Recursion Pharmaceuticals (RXRX) is gaining investor attention following its updated presentation at the J.P. Morgan Healthcare Conference, which featured early REC-4881 data and a projected cash runway into 2027. Despite recent positive momentum with a 10.71% year-to-date share price return, the company's longer-term performance remains weak. The article suggests that while RXRX trades below its intrinsic value and analyst targets, its early-stage and loss-making status raises questions about whether its future growth is already priced in.
Taylor, CFO of Recursion Pharmaceuticals, sells $89k in shares By Investing.com
Ben R. Taylor, CFO of Recursion Pharmaceuticals (NASDAQ: RXRX), sold 21,383 shares for $89,380 on December 29, 2025, through a Rule 10b5-1 trading plan. Despite the insider sale, Recursion Pharmaceuticals recently reported positive Phase 1b/2 results from its TUPELO trial for REC-4881, leading JPMorgan to upgrade the stock to Overweight with an $11 price target. The drug demonstrated significant efficacy in treating familial adenomatous polyposis (FAP).
How Recursion’s AI Drug Platform Progress And Extended Runway At Recursion Pharmaceuticals (RXRX) Has Changed Its Investment Story
Recursion Pharmaceuticals (RXRX) recently presented at the J.P. Morgan Healthcare Conference, highlighting its AI-enabled drug discovery platform, clinical progress with REC-4881, and over $500 million in partnership payments. The company also announced an extended cash runway through 2027, aiming to balance platform investment with financial durability. While the AI-driven platform and financial longevity reshape its investment narrative, the reliance on external funding and potential for future dilution remain key considerations for investors, alongside highly varied fair value estimates.
Why Recursion Pharmaceuticals (RXRX) Is Up 10.7% After Positive REC-4881 Trial Data And Rising Analyst Focus
Recursion Pharmaceuticals (RXRX) saw a 10.7% stock increase following positive Phase 1b/2 TUPELO trial data for its MEK 1/2 inhibitor REC-4881 and heightened analyst attention. The company's AI-enabled drug discovery model is now under sharper focus as a potential key value driver. Despite optimism from clinical data and analyst upgrades, investors are cautioned about the company's cash burn and a limited cash runway through Q4 2027.
Is Recursion Pharmaceuticals (RXRX) Mispriced After Volatile Share Performance And Ongoing Tech Partnerships
Recursion Pharmaceuticals (RXRX) has experienced volatile share performance, with recent gains but significant declines over the past year. Simply Wall St's analysis suggests the stock is undervalued, estimating an intrinsic value of $9.36 per share compared to its current price of $4.37 using a Discounted Cash Flow model, and also appears undervalued based on its Price-to-Book ratio. The article highlights the company's focus on applying technology to drug discovery and its partnerships as key factors influencing investor sentiment.
Recursion Pharmaceuticals (RXRX): Assessing Valuation After New Activist Investor Filings With the SEC
Activist investor filings regarding Recursion Pharmaceuticals (RXRX) are drawing attention to the stock, which has experienced significant share price declines over the past year. Despite its AI-driven drug discovery approach and rapid revenue growth, the company is currently unprofitable. Shares are trading at a discount to Wall Street's price target, leading to a valuation debate on whether it's an undervalued AI biotech or if the market has already factored in future risks related to partnerships and cash burn.
Taylor, CFO of Recursion Pharmaceuticals, sells $89k in shares
Ben R. Taylor, CFO of Recursion Pharmaceuticals (NASDAQ: RXRX), sold 21,383 shares for $89,380 on December 29, 2025, under a Rule 10b5-1 trading plan. Following this transaction, Taylor still directly owns 761,550 shares of the company's Class A Common Stock. This insider sale comes amidst other company news, including positive Phase 1b/2 results for their investigational drug REC-4881 and an upgrade from JPMorgan.
Recursion Pharmaceuticals Reports Positive Phase 1b/2 TUPELO Trial Results, Validating AI-Driven Therapy for FAP
Recursion Pharmaceuticals announced positive Phase 1b/2 results from its TUPELO trial for REC-4881, an AI-discovered drug for Familial Adenomatous Polyposis (FAP). The trial demonstrated rapid clinical activity and significant durability, suggesting the drug shrinks polyps and halts disease progression. The company plans to engage with the FDA in H1 2026 to discuss a potential registration pathway and is expanding the trial to include younger patients.
Is Recursion (RXRX) Finally Proving Its AI Drug Discovery Model With REC-4881’s Early Data?
Recursion Pharmaceuticals is gaining confidence in its AI drug discovery platform, notably with positive Phase 1b/2 data for REC-4881, leading to increased institutional ownership and an upgrade from J.P. Morgan. While this strengthens the near-term outlook for the AI-first approach translating into commercially viable assets, investors remain cautious about the company's high cash burn and dependence on future funding. The positive results for REC-4881 in FAP, showing meaningful polyp burden reductions, represent a crucial test for the platform's potential.
Recursion Pharmaceuticals RXRX Stock News and Forecasts on December 21 2025
As of December 21, 2025, investors in Recursion Pharmaceuticals (NASDAQ: RXRX) are closely watching the impact of new clinical data on the company's "AI drug discovery" promise. Positive Phase 1b/2 results for REC‑4881 in familial adenomatous polyposis (FAP) have led to a JPMorgan upgrade and an increased price target of $11, signaling potential for a significant re-rating if the platform can deliver commercial revenue. However, the company faces challenges including high cash burn and the overhang of 7.09 million shares registered for resale by Tempus AI.
RXRX Stock: Analyzing the Dive and Its Impact
Recursion Pharmaceuticals Inc. (RXRX) stock experienced a -4.49% decline amid concerns over market confidence, compounded by a significant insider share sale. Despite a strong current ratio, the company faces financial challenges with negative margins and steep losses due to heavy research and development expenditure. The article analyzes these financial movements and their implications for investor sentiment and future market positioning.
Recursion Pharmaceuticals Stock Is Soaring Today: Here's Why
Recursion Pharmaceuticals (NASDAQ: RXRX) stock rose sharply today after JPMorgan upgraded its rating to Overweight with an increased price target of $11. The upgrade was driven by confidence in Recursion's AI-driven drug discovery platform, particularly the "blockbuster potential" of REC‑4881 and promising early results for REC‑617. The company's AI-driven approach is also gaining attention as major AI players like OpenAI and Anthropic are reportedly exploring partnerships with biotechs.
